background
compet
incompat
classif
system
intern
committe
nomenclatur
virus
icnv
establish
establish
univers
taxonom
scheme
one
import
principl
embodi
scheme
develop
idea
virus
group
accord
share
properti
second
focu
nucleic
acid
genom
primari
criterion
classif
viral
genom
take
varieti
form
dna
rna
doubl
strand
singl
strand
segment
plu
minu
polar
circular
linear
smallest
genom
thousand
nucleotid
kb
contain
gene
structur
protein
essenti
enzym
larger
virus
genom
kb
includ
complex
regulatori
element
overal
taxonom
system
identifi
four
characterist
use
classif
virus
natur
nucleic
acid
virion
symmetri
capsid
presenc
absenc
outer
lipid
envelop
dimens
virion
capsid
advent
readili
avail
autom
nucleic
acid
sequenc
possibl
obtain
precis
inform
viral
genom
sequenc
data
mean
quantit
measur
related
made
construct
accur
famili
tree
use
specialist
softwar
fact
rapid
evolut
rna
viral
gene
particular
may
enabl
investig
differenti
lineag
outbreak
help
identifi
chain
infect
level
individu
host
formal
taxonom
usag
first
letter
viru
famili
subfamili
genu
name
capitalis
term
print
ital
speci
design
capitalis
italicis
follow
repres
exampl
full
formal
taxonom
terminolog
order
mononegaviral
famili
paramyxovirida
subfamili
paramyxovirina
genu
respiroviru
speci
parainfluenza
viru
type
compar
sequenc
data
identifi
genotyp
clade
mani
criteria
use
group
virus
hierarch
classif
system
may
found
intern
committe
taxonomi
virus
ictv
websit
summari
follow
boom
respiratori
virolog
speci
rhinovirus
coronavirus
enterovirus
adenovirus
parainfluenza
virus
respiratori
syncyti
viru
ad
influenza
measl
virus
caus
respiratori
tract
infect
restrict
patient
group
immunocompromis
member
famili
herpesvirus
includ
herp
simplex
cytomegaloviru
varicellazost
viru
epsteinbarr
viru
human
herp
viru
also
associ
respiratori
diseas
list
pathogen
extend
last
year
discoveri
novel
viru
human
metapneumoviru
antigen
distinct
virus
document
caus
sporad
epidem
respiratori
infect
infant
children
adult
howev
vari
divers
group
divid
among
six
distinct
famili
understand
basic
biolog
famili
give
insight
possibl
strategi
diagnosi
control
therapi
elsevi
scienc
ltd
right
reserv
exampl
picornaviru
famili
enteroviru
genu
famili
virus
includ
success
respiratori
pathogen
caus
epidem
major
medic
veterinari
import
tabl
genom
consist
singl
strand
neg
polar
rna
linear
arrang
around
six
gene
virus
must
carri
rna
polymeras
viral
particl
incom
viral
rna
neither
translat
copi
cellular
machineri
virus
envelop
surfac
project
surround
nucleocapsid
project
major
protect
antigen
induc
neutralis
antibodi
resist
infect
mump
particularli
measl
viru
infect
continu
caus
high
level
morbid
mortal
develop
countri
larg
control
vaccin
elsewher
mean
control
infect
caus
respiratori
syncyti
viru
rsv
parainfluenza
virus
piv
human
metapneumovirus
hmpv
focu
much
current
research
molecular
virolog
rsv
piv
well
understood
form
basi
build
vaccinedevelop
programm
genom
rsv
encod
subgenom
messeng
rna
mrna
mrna
translat
known
protein
four
nucleocapsid
protein
nucleocapsid
n
protein
phosphoprotein
p
larg
polymeras
subunit
l
transcript
elong
factor
three
transmembran
envelop
glycoprotein
fusion
f
protein
attach
g
protein
small
hydrophob
sh
protein
two
nonstructur
protein
matrix
protein
rna
regulatori
factor
g
f
glycoprotein
major
protect
antigen
induc
rsvneutralis
antibodi
resist
infect
order
genom
rsv
appear
subspeci
level
two
antigen
group
rsv
divid
basi
reaction
panel
monoclon
antibodi
isol
group
b
circul
concurr
epidem
revers
transcript
polymeras
chain
reaction
rtpcr
part
g
gene
follow
restrict
enzym
digest
analysi
rapid
techniqu
use
cane
et
al
screen
sampl
obtain
estim
genom
variabl
within
epidem
epidem
found
made
number
differ
genotyp
could
consid
aggreg
separ
concurr
epidem
genotyp
circul
uk
similar
found
part
world
evid
certain
genotyp
pathogen
other
genet
map
piv
similar
rsv
encod
n
p
f
l
protein
distantli
relat
function
counterpart
protein
rsv
howev
human
piv
lack
sh
protein
piv
p
gene
give
rise
addit
accessori
protein
two
protect
antigen
piv
hn
haemagglutininneuraminidas
attach
protein
f
protein
order
genom
appear
technic
difficult
develop
vaccin
virus
replic
sole
mucos
surfac
effort
focus
develop
liveattenu
intranas
administ
rsv
piv
vaccin
histor
vaccin
two
virus
base
inactiv
viru
purifi
protein
associ
sever
diseas
vaccine
live
vaccin
appear
induc
immun
without
diseas
enhanc
attenu
virus
current
design
vitro
use
revers
genet
technolog
infecti
viru
produc
entir
cdna
predetermin
chang
nucleotid
sequenc
introduc
infecti
viru
way
cdna
intermedi
use
technolog
may
also
possibl
creat
chimer
vaccin
strain
gene
exampl
sever
differ
paramyxoviru
f
protein
recent
van
den
hoogen
et
al
report
isol
hmpv
nasopharyng
aspir
taken
young
children
netherland
data
report
suggest
hmpv
similar
rsv
infect
occur
winter
month
common
childhood
subsequ
show
high
percentag
sequenc
ident
avian
pneumoviru
serotyp
c
apvc
aetiolog
agent
respiratori
diseas
bird
apv
belong
metapneumoviru
genu
togeth
pneumoviru
genu
constitut
pneumovirina
subfamili
tabl
classif
two
genera
base
primarili
gene
constel
metapneumovirus
lack
nonstructur
protein
gene
order
differ
pneumovirus
rsv
shown
relationship
hmpv
apvc
close
two
subgroup
rsva
b
howev
relationship
reflect
host
rang
sinc
apv
infect
bird
contrast
hmpv
sequenc
analysi
cultur
hmpv
isol
suggest
famili
virus
includ
three
genera
influenza
viru
b
c
genom
consist
singl
strand
rna
segment
eight
fragment
code
protein
rna
protect
close
associ
nucleoprotein
np
form
helic
structur
around
call
nucleocapsid
np
typespecif
antigen
occur
one
three
form
provid
basi
classif
human
influenza
virus
b
c
outer
layer
influenza
virus
compos
lipid
bilay
acquir
viru
bud
host
cell
cytoplasm
membran
two
import
glycoprotein
insert
membran
give
viru
spiki
appear
electron
microscop
first
glycoprotein
haemagglutinin
ha
function
attach
viru
receptor
surfac
respiratori
cell
second
glycoprotein
radiat
surfac
viru
particl
neuraminidas
na
involv
releas
newli
form
particl
surfac
infect
cell
addit
virus
infect
human
influenza
also
infect
anim
speci
bird
pig
hors
plausibl
theori
origin
novel
pandem
strain
new
subtyp
fact
reassort
virus
result
doubl
infect
singl
host
cell
possibl
genom
made
discret
segment
major
antigen
shift
seen
influenza
b
c
virus
infect
human
antigen
differ
ha
na
glycoprotein
provid
basi
classif
influenza
subtyp
practic
import
classif
crossimmun
confer
differ
subtyp
antigen
differ
vital
monitor
epidem
across
world
vaccin
product
current
total
distinct
recognis
among
influenza
virus
antigen
differ
also
occur
na
antigen
nine
subtyp
identifi
among
human
avian
speci
technic
possibl
refer
laboratori
influenza
isol
either
b
follow
place
isol
laboratori
number
year
isol
follow
subtyp
design
parenthes
thu
influenza
viru
ahong
signifi
influenza
viru
isol
patient
hong
kong
subtyp
recent
subtyp
affect
human
occur
hong
kong
case
record
six
die
influenza
subtyp
transmit
chicken
howev
humantohuman
transmiss
document
two
recent
case
region
show
potenti
devast
consequ
avian
influenza
subtyp
trigger
pandem
human
influenza
control
influenza
among
highrisk
group
depend
annual
vaccin
use
inactiv
vaccin
formul
current
epidem
type
two
strain
type
b
one
strain
intranas
administ
live
attenu
vaccin
may
accept
children
provid
longer
last
immun
studi
current
underway
assess
addit
benefit
vaccin
inactiv
vaccin
highrisk
popul
two
approv
antivir
drug
known
neuraminidas
inhibitor
avail
treatment
prevent
influenza
type
b
infect
older
children
adult
zanamivir
given
inhal
oseltamivir
given
oral
controversi
surround
use
drug
clinic
signific
sideeffect
toler
treatment
mild
selflimit
infect
treatment
initi
within
h
initi
symptomatolog
ration
use
neuraminidas
inhibitor
depend
larg
extent
avail
rapid
diagnost
test
pointofcar
test
nearpati
test
avail
kitform
utilis
enzymeimmunoassaybas
technolog
test
perform
room
temperatur
specialist
equip
nonlaboratori
personnel
assay
detect
viru
antigen
min
sensit
specif
rang
respect
rtpcr
sensit
diagnost
test
allow
use
minim
invas
specimen
howev
test
take
hour
complet
current
format
like
play
role
decis
initi
antivir
therapi
institut
control
infect
procedur
picornaviru
famili
divers
group
human
pathogen
includ
enterovirus
rhinovirus
togeth
constitut
common
caus
infect
human
develop
world
tabl
genom
singl
strand
sens
rna
encod
singl
polyprotein
amino
acid
polyprotein
cleav
highli
specif
manner
proteas
produc
structur
molecul
protein
involv
viral
replic
nonenvelop
capsid
consist
dens
pack
icosahedr
arrang
protom
consist
four
polypeptid
deriv
cleavag
origin
protom
viral
particl
small
henc
picorna
nm
diamet
length
genom
nm
consequ
tightli
pack
capsid
human
rhinovirus
includ
serotyp
two
main
group
base
cellular
receptor
rhinoviru
serotyp
use
intracellular
adhes
molecul
cell
receptor
attach
approxim
serotyp
attach
lowdens
lipoprotein
ldl
receptor
review
rhinovirus
found
articl
savolainen
issu
mani
enteroviru
ev
infect
accompani
nonspecif
usual
mild
respiratori
ill
review
evassoci
respiratori
ill
found
case
present
upper
respiratori
tract
infect
respiratori
distress
pneumonia
otiti
media
other
present
bronchiol
croup
sore
throat
initi
ev
alloc
four
speci
basi
pathogenesi
human
experiment
anim
polioviru
pv
coxsackieviru
b
cva
cvb
echoviru
e
use
serotyp
specif
sera
enterovirus
classifi
serotyp
eg
cv
cv
biolog
sequenc
analysi
indic
two
picornavirus
echoviru
number
import
featur
distinguish
picornavirus
highli
diverg
sequenc
show
major
differ
capsid
protein
evid
classifi
new
genu
parechoviru
design
human
parechoviru
respect
develop
molecular
biolog
techniqu
mean
classifi
identifi
ev
chang
serotyp
assay
genom
analysi
reclassif
ev
basi
nucleotid
deduc
amino
acid
sequenc
approv
intern
committe
taxonomi
virus
ictv
ev
serotyp
genu
enteroviru
group
five
speci
human
ev
ae
inclus
ishiko
et
al
develop
rapid
reliabl
method
base
rtpcr
sequenc
region
place
clinic
isol
one
five
speci
ev
like
rna
virus
high
mutat
rate
lack
proofread
activ
genom
replic
estim
approxim
one
mutat
gener
per
newli
synthesis
genom
ev
mutat
rate
million
time
higher
human
genom
ishiko
et
al
state
higher
mutat
rate
advantag
phylogenybas
classif
enabl
detail
molecular
epidemiolog
studi
even
use
short
region
genom
base
pair
complet
apart
huge
public
health
impact
polioviru
vaccin
programm
control
therapeut
strategi
ev
infect
otherwis
spars
immunoglobulin
use
prophylact
therapeut
ev
infect
neonat
immunocompromis
patient
anecdot
report
clinic
success
antivir
drug
pleconaril
broad
activ
member
picornaviru
famili
doubl
blind
placebocontrol
trial
patient
age
year
receiv
either
mg
pleconaril
three
time
per
day
placebo
receiv
pleconaril
shorter
durat
headach
faster
resolut
symptom
asept
mening
question
remain
whether
benefit
drug
worthi
widespread
use
howev
control
picornaviru
infect
like
achiev
antivir
approach
rather
vaccin
xray
crystallograph
studi
reveal
precis
threedimension
structur
picornaviru
capsid
way
interact
cell
receptor
basi
studi
drug
pleconaril
design
block
viral
attach
host
cell
similar
drug
follow
coronavirida
small
number
epidemiolog
studi
suggest
human
coronavirus
second
rhinovirus
caus
common
cold
account
mild
upper
respiratori
tract
infect
adult
human
coronavirus
difficult
human
respiratori
virus
detect
laboratori
grow
well
cell
cultur
detect
routin
diagnost
virolog
laboratori
coronavirus
first
isol
year
ago
organ
cultur
human
embryon
trachea
nasal
epithelium
primari
human
kidney
cell
cultur
major
human
coronavirus
cultur
vitro
sinc
serolog
relat
one
two
refer
strain
oc
stand
organ
cultur
molecular
analysi
shown
two
prototyp
virus
differ
substanti
repres
differ
speci
group
speci
group
speci
respect
coronaviru
genom
strand
rna
extraordinari
size
complex
compos
approxim
kb
largest
known
autonom
replic
rna
anoth
uniqu
featur
virus
twothird
genom
devot
encod
protein
involv
replic
transcript
viral
rna
strand
rna
virus
evolv
differ
mechan
mrna
synthesi
one
allow
structur
nonstructur
protein
gener
need
greater
lesser
quantiti
respect
separ
produc
latter
express
fulllength
strand
genom
rna
structur
protein
aris
five
subgenom
mrna
nucleocapsid
protein
n
surround
viral
nucleic
acid
mediums
virus
nm
pleomorph
outer
lipid
envelop
dissolv
ether
electron
microscop
particl
clubshap
surfac
project
spike
give
appear
reminisc
crown
latin
corona
crown
group
speci
also
contain
addit
envelop
protein
haemagglutininesteras
protein
remark
sequenc
ident
equival
protein
influenzaviru
c
protein
induc
virusneutralis
antibodi
consequ
could
like
compon
put
subunit
vaccin
perhap
gener
unavail
routin
diagnost
test
restrict
demand
control
viru
infect
vaccin
use
antivir
drug
recent
advent
molecular
amplif
test
grow
use
realtim
pcr
give
better
appreci
level
morbid
children
vulner
group
rtpcrhybridis
test
develop
vabret
et
al
amplifi
section
gene
code
smaller
membran
protein
respiratori
specimen
sputum
nasal
aspir
test
system
coronavirus
detect
author
conclud
test
would
use
investig
role
human
coronavirus
infect
respiratori
tract
contrast
coronavirus
mani
member
adenoviru
famili
readili
propag
routin
laboratori
cell
cultur
system
establish
virus
associ
acut
respiratori
infect
could
maintain
lowlevel
persist
infect
lymphat
tissu
adenoviru
genom
linear
doublestrand
dna
molecul
contain
kb
pair
code
least
differ
structur
polypeptid
viral
particl
compar
small
nm
nonenvelop
icosahedron
stabl
low
ph
bile
proteolyt
enzym
molecular
biolog
virus
understood
great
detail
unlik
rna
respiratori
virus
discuss
far
viral
dna
replic
proce
much
higher
level
fidel
viral
dna
polymeras
possess
intrins
exonucleas
preferenti
excis
mismatch
nucleotid
duplex
dna
recent
experi
shown
mutat
impair
exonucleas
activ
dna
polymeras
greatli
increas
rate
mutat
viral
genom
classif
human
adenovirus
base
nucleotid
sequenc
differ
genom
distinct
virus
virus
also
display
characterist
gc
content
dna
exploit
use
enzym
smai
cleav
specif
ccc
ggg
run
digest
dna
agaros
slab
gel
possibl
obtain
pattern
uniqu
six
speci
tabl
techniqu
provid
effici
mean
identif
classif
unknown
strain
method
differenti
six
speci
includ
gc
haemagglutin
pattern
oncogen
serotyp
adenoviru
infect
mani
year
success
control
among
young
militari
recruit
usa
use
live
entericco
oral
vaccin
serotyp
use
associ
reduct
overal
respiratori
ill
reduct
adenovirusspecif
ill
rate
recruit
use
similar
vaccin
among
paediatr
popul
investig
howev
observ
show
potenti
public
health
benefit
use
crude
vaccin
prepar
greater
concern
adenoviru
infect
occur
follow
stem
cell
transplant
associ
mortal
low
lymphocyt
count
signific
predictor
adenoviru
infect
recoveri
turn
significantli
delay
patient
receiv
campath
vivo
cidofovir
broadspectrum
antidna
viral
agent
shown
therapeut
benefit
lifethreaten
adenovir
diseas
patient
cidofovir
cystidin
nucleosid
phosphon
analogu
invitro
invivo
activ
spectrum
virus
includ
herpesvirus
adenovirus
realtim
quantit
pcr
detect
adenoviru
genom
whole
blood
transform
monitor
infect
posttranspl
period
antivir
therapi
requir
weekli
quantit
viral
load
help
assess
therapi
experi
treatment
schedul
may
last
mani
week
herpesviru
infect
remain
signific
caus
respiratori
morbid
iatrogen
immunosuppress
individu
despit
advanc
diagnosi
antivir
therapi
herpesvirus
involv
respiratori
complic
posttranspl
period
cytomegaloviru
cmv
herp
simplex
hsv
varicellazost
viru
vzv
role
human
remain
substanti
undefin
may
complex
interact
virus
exampl
cmv
caus
respiratori
diseas
herpesvirida
larg
famili
envelop
doublestrand
dna
virus
genom
tightli
wound
enclos
icosadelthedr
capsid
nm
diamet
envelop
surround
capsid
glycoprotein
spike
project
provid
antigen
determin
individu
member
group
featur
common
virus
follow
infect
establish
latent
infect
persist
life
host
reactiv
product
progeni
viru
may
occur
interv
especi
period
immunosuppress
produc
recurr
infect
virus
compar
complex
genom
code
mani
enzym
involv
nucleic
acid
metabol
ictv
divid
herpesvirida
famili
subfamili
basi
differ
biolog
properti
variou
virus
tabl
control
cmv
hsv
vzv
infect
immunosuppress
patient
reli
appropri
use
antivir
drug
aciclovir
ganciclovir
recent
live
varicella
vaccin
licens
prevent
varicella
vaccin
well
heatinactiv
formul
also
found
enhanc
immun
vzv
healthi
person
inactiv
varicella
vaccin
given
stemcel
transplant
first
day
thereaft
reduc
risk
zoster
protect
correl
reconstitut
tcell
immun
vzv
last
year
qualit
quantit
assay
diagnosi
cmv
epsteinbarr
viru
includ
estim
viral
load
realtim
pcr
detect
whole
blood
similarli
quantit
dna
investig
defin
pathogen
role
clinic
cutoff
threshold
valu
appear
clinic
symptom
defin
cmv
epsteinbarr
viru
valu
repres
basi
select
limit
viral
load
initi
antivir
treatment
accord
preemptiv
therapi
strategi
molecular
amplif
assay
supersed
viral
cultur
diagnosi
hsv
vzv
infect
greater
avail
molecular
amplif
sequenc
technolog
provid
data
measur
viral
related
diagnost
tool
infect
would
otherwis
undetect
elus
infect
includ
caus
coronavirus
human
metapneumoviru
molecular
amplif
techniqu
gener
restrict
region
centr
unlik
provid
rapid
diagnosi
requir
utilis
newer
antivir
drug
control
infect
procedur
pointofcaretest
impact
front
develop
new
vaccin
paramyxovirus
show
promis
ultim
provid
huge
public
health
benefit
antivir
drug
appear
best
option
treat
enteroviru
rhinoviru
adenoviru
infect
number
serotyp
preclud
vaccin
develop
immunocompromis
patient
requir
regular
quantit
realtim
pcr
monitor
evid
dissemin
